CreosG strengthens cooperation with UN-affiliated international organizations... "Accelerating pandemic response vaccine development"

CreoSG announced on the 28th that its subsidiary ImmunoVaxBio is continuously strengthening its collaboration with the International Vaccine Institute (IVI) centered on its self-developed 'Universal Vaccine and New Drug Development Platform (SUV-MAP).' ImmunoVaxBio plans to expand its vaccine pipeline and accelerate commercialization through joint research and development with IVI.

IVI is an international organization under the UN that operates with the purpose of developing vaccines for infectious diseases prevalent worldwide. Supported by the Bill & Melinda Gates Foundation, founded by Microsoft co-founder Bill Gates, and with member countries including various nations and the World Health Organization (WHO), collaboration with IVI offers strong advantages in conducting global clinical trials and regulatory approval processes.

Since 2018, ImmunoVaxBio has signed a memorandum of understanding (MOU) with IVI and has been cooperating on various vaccine developments. Previously, the two parties jointly developed vaccines during the COVID-19 pandemic, and in 2020, they signed a contract for preclinical research services for a COVID-19 vaccine with IVI.

ImmunoVaxBio plans to continue joint vaccine development with IVI centered on SUV-MAP. SUV-MAP applies recombinant VSV technology, which not only maximizes vaccine safety and immune response but also allows candidate substances to be confirmed within five months after a pandemic outbreak. The company explains that rapid development of various vaccines will be possible based on the synergy between IVI's infrastructure and SUV-MAP.

A company representative stated, “ImmunoVaxBio is currently conducting various national vaccine development projects together with IVI and plans to continue cooperation in the future. We have confirmed preventive efficacy and safety in vaccines jointly developed with IVI, including COVID-19, Zika, MERS, and SFTS vaccines, and based on this, we have launched SUV-MAP, which can be applied to various vaccines, accelerating vaccine development.”

He added, “As new infectious disease viruses mutate faster and more diversely, responding to them is becoming more difficult. Applying the recently launched SUV-MAP enables rapid discovery of vaccine candidates, and we expect the synergy with IVI to be maximized.”